Protagonist Therapeutics Inc. discontinued a Phase IIb study for the experimental ulcerative colitis treatment PTG-100 following a review from an Independent Data Monitoring Committee (DMC).
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
Pfizer Inc. said the company’s study to test safety and effectiveness of its anti-smoking treatment Chantix in adolescent smokers failed to meet the main goal.
Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS
Novartis announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis were published in the peer-reviewed journal The Lancet.
Shares of Array BioPharma Inc. climbed after the company released detailed results for its late-stage combination treatment for metastatic melanoma.
AbbVie Inc. said the drugmaker would not seek accelerated approval for the company’s experimental lung cancer treatment based on the results from a mid-stage study.
Roche’s immunotherapy Tecentriq racked up a third trial win in combination with other cancer drugs, a boost for the Swiss drugmaker.
Regeneron Pharmaceuticals announced positive top-line data from the Phase III PANORAMA study of Eylea (aflibercept) injection in moderately severe to severe non-proliferative diabetic retinopathy.
Heron Therapeutics said the company’s late-stage anesthetic used to treat bunionectomy and hernia repair hit all primary and key secondary endpoints in two Phase III trials that cut down on the requirement of opioid drugs to treat pain.
At-home consumption and gourmet beverages have Americans drinking a daily cup of coffee at the highest level since 2012.
Smokers may be more likely to develop hearing loss than nonsmokers, and the risk increases with each additional cigarette people smoke on a typical day, a Japanese study suggests.
Auris Medical AG announced that the Swiss-based company’s Phase III tinnitus trial for Keyzilen failed to meet endpoints.
AbbVie and Neurocrine Biosciences announced that the Phase III ELARIS UF-II clinical trial of elagolix for uterine fibroids met its primary endpoint.
Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded.
In the past few years, personal fitness trackers have become all the rage. It’s fun to see your daily activity level, sleep quality and heart rate. But, does knowing this data lead to any positive changes?
Realm Therapeutics Inc.’s PR013 failed to show efficacy in its Phase II trial for allergic conjunctivitis.
Anthera Pharmaceuticals Inc. is evaluating all strategic options after the company’s lead drug failed in a late-stage trial, sending shares down 80 percent in premarket trading.
AstraZeneca expects a key lung cancer study of two immunotherapy drugs to produce overall survival results in the second half of 2018, rather than the first half.
Shares of MyoKardia climbed after the company revealed positive results from a mid-stage clinical trial for obstructive hypertrophic cardiomyopathy.
Sanofi and Evotec started exclusive talks over accelerating research into the treatment of infectious diseases and will form a new open innovation platform in this area, led by Evotec.
Eisai and Merck agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib mesylate), an orally available tyrosine kinase inhibitor.